Kezar Life Sciences, Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • KZR-616
    • KZR-261
  • Our Science
    • Overview
    • Medical & Scientific Presentations
    • Publications
  • Clinical Trials
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Press Releases

Investors & News

Investors & News

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact the Board
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting

Apr 10, 2021 8:30am EDT

Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates

Mar 11, 2021 4:01pm EST

Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference

Feb 25, 2021 4:01pm EST

Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference

Feb 10, 2021 4:01pm EST

Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

Jan 07, 2021 4:02pm EST

Kezar Life Sciences Added to the Nasdaq Biotechnology Index

Dec 14, 2020 4:01pm EST

Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences

Nov 12, 2020 4:05pm EST

Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates

Nov 05, 2020 4:01pm EST

Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020

Nov 05, 2020 8:46am EST

Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis

Oct 23, 2020 7:00am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Kezar Life Sciences, Inc.
  • About Us
  • Pipeline
  • Our Science
  • Clinical Trials
  • Investors & News
  • Careers
Contact Us

4000 Shoreline Court , Suite 300
South San Francisco, CA 94080

Linkedin Facebook Twitter YouTube

© 2021 Kezar Life Sciences, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap